Shares in Omega Diagnostics closed more than 10% lower yesterday following a media report that one of its Covid test partners is allegedly set to sue the government for “stonewalling” approval of its kit for use in the UK. 

The article also said that Mologic, Omega’s partner on the Visitect Covid-19 antigen test, has asked for its kit to be evaluated by the government’s Porton Down science lab with an independent observer present. The test has reportedly fallen short because of “kit failure” or being too difficult to administer. 

Omega’s headquarters in Alva will be one of the sites producing tests on behalf of the Department of Health and Social Care (DHSC) once it has named its preferred test, a decision that was expected weeks ago. The Mologic test is among those under consideration.

READ MORE: Omega shares slip as decision delayed on which Covid test it will produce

Mologic’s lateral flow antigen test, which determines whether someone is currently infected with the virus, is also being commercialised by Omega under the Visitect brand for sale to other parts of the world

In a statement released yesterday, Omega said the situation between Mologic and the government will have no impact on its agreement with the DHSC, which could be worth up to £374 million over the lifetime of the contract. 

Shares in AIM-listed Omega closed 7p lower yesterday at 62.5p.